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Nearly 80% of breast cancer are hormone receptor positive. The efficacy of hormonal adjuvant
therapy of breast cancer was expressed in the most recent EBCTG overview analysis of ran-
domised trials using adjuvant tamoxifen. Five years of adjuvant tamoxifen led to proportional
risk reduction, in terms of recurrence andmortality for hormone receptor positive patients, of
47% and 26%, respectively. This benefit was constant, regardless ofmenopausal status, age or
whether or not chemotherapy was administered. More recent trials evaluating the use of aro-
matase inhibitors have challenged the standard of hormonal therapy in post-menopausal
patients. However, many questions have been raised from these trials: (a) the optimal man-
agement of patients with hormone receptor positive breast cancer in terms of selection of
hormonal agents and its sequence and duration; (b) the role of ovarian suppression in
pre-menopausal patients; and (c) the actual role of biomolecular markers in clinical decision.
 2008 Elsevier Ltd. All rights reserved.1. Introduction
Hormone treatment of early breast cancer has a different ap-
proach according to menopausal status. In pre-menopausal
patients, the usual treatment of hormone positive breast can-
cer is tamoxifen, with or without ovarian function suppres-
sion.1 In post-menopausal patients with hormone positive
breast cancer, aromatase inhibitors represent a good alterna-
tive to tamoxifen. These agents have been used in different
strategies: after surgery (up-front),2,3 or sequentially, that is
after 2 or 3 years of tamoxifen (early switch),4–9 or after 5
years of tamoxifen (extended switch).10–13
2. Tamoxifen as adjuvant hormonal therapy
in pre-menopausal patients
Nearly 20% of all breast cancers occur in women younger than
50 years. Amongst them 60% show positive expression of bother Ltd. All rights reserved
Lorusso).oestrogen (ER) and progesterone (PGR) receptors. The main-
stay of adjuvant endocrine therapy in pre-menopausal pa-
tients is tamoxifen; its efficacy was first showed in multiple
trials started in 1980s.14–16 The most recent Oxford Overview
underlines the efficacy of 5 years of tamoxifen in women with
ER positive or unknown receptors, with 41% reduction of
annual recurrence rate, 34% reduction of annual mortality
and 39% reduction in the annual risk of controlateral breast
cancer.17 Moreover, this benefit is consistent and similar in
women across age.17 The duration of tamoxifen therapy
beyond 5 years is still under investigation. In fact, the
NSABP-B14 trial which enrolled women ER+, node negative,
only 26% of whom younger than 50 years showed a worse dis-
ease free survival (DFS) with longer use of tamoxifen. A criti-
cism to this trial could be that it enrolled only node negative
patients, only a small part of them being under the age of 50,
thus leaving uninvestigated the possible beneficial effect of
longer tamoxifen therapy in node positive patients, i.e. in a
population with an increased risk of recurrence.18 An attempt
to solve this question was done by the ATLAS trial (The Adju-
vant Tamoxifen, Longer Against Shorter) which randomised
.
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completed 5 years of tamoxifen, to continue tamoxifen for 5
more years, or control. An update of this trial reported that
there was no statistical difference in overall mortality
between the two groups. However, continuation of tamoxifen
beyond five years reduced recurrence rate, although longer
follow-up is needed to assess long-term effects on
mortality.19
Pre-menopausal patients included in the Oxford Overview
have a reduction of annual risk of death of 38% with tamoxi-
fen plus chemotherapy.17 In the subgroup analysis of patients
younger than 50 with ER+, the association of chemotherapy
with tamoxifen showed a reduction of the recurrence rate
at 5 years by 21.6% versus 14% for tamoxifen alone, with an
absolute benefit of 7.6%.17 However, the patients younger
than 50 years included in the Oxford Overview were only
177, and the chemotherapy regimen used was not anthracy-
cline based. More recently IBCSG (International Breast Cancer
Study Group) trial 13-93 study randomised 1246 node positive
pre-menopausal patients to receive tamoxifen for 5 years or
not, after chemotherapy with anthracycline. DFS was better
for chemotherapy plus tamoxifen in pre-menopausal patients
with ER positive and high risk of recurrence, while no differ-
ence in OS emerged.20 Chemotherapy amenorrhea was re-
lated to better DFS in patients with ER+ tumours, giving an
indirect information on the importance of ovarian function
suppression by chemotherapy. Moreover, no interaction was
observed between tamoxifen and chemotherapy amenorrhea,
thus indicating that iatrogenic amenorrhea must not be con-
sidered an alternative to tamoxifen.20 IBCSG trial 11-93 inves-
tigated also on the possibility to avoid chemotherapy for
pre-menopausal patients with ER+, intermediate risk accord-
ing to St. Gallen criteria: randomising patients to chemother-
apy plus ovarian ablation/suppression (OAS) and tamoxifen
versus OAS plus tamoxifen. No difference in terms of DFS
was evident across the arms. The trial closed prematurely
due to its slow accrual, thus it resulted strongly underpow-
ered to exclude the role of chemotherapy in these patients.21
With regard to the timing of administration of tamoxifen, it
was well established by SWOG INT 0100 study, in which
post-menopausal patients treated with concomitant tamoxi-
fen and chemotherapy showed a slightly worse DFS and OS
as compared to patients treated with tamoxifen given
sequentially to chemotherapy.22Table 1 – Summary of findings of the LHRH agonists in early b
Treatment Recurrence
HR 95% CI
LHRH versus no therapy n = 338 0.72 0.49–1.04
LHRH + T versus T n = 1013 0.85 0.67–1.09
CT + LHRH versus CT –24.7 –39.5 to –6.2
640 years; n = 714
P40 years; n = 1.662 –5.1 –20.1 to 12.7
CT + –T + LHRH versus CT + –T –25.2 –39.4 to –7.7
640 years; n = 795
P40 years; n = 1.946 –3.9 –18.1 to 12.9
LHRH versus CT n = 3184 1.04 0.92 to 1.17
Abbreviations: LHRH, luteinising hormone-releasing hormone; HR, hazard3. Subgroups of adverse prognosis and benefit
of hormonal therapy
Nearly 20% of ER+ breast cancers are PGR negative. The role of
PGR has been investigated for a long time. Nowadays, it is
generally accepted that ER+ PGR– patients identify a more
aggressive subtype of breast cancer with a poor prognosis,
perhaps correlated with a worse response to endocrine treat-
ment. Clinical trials investigated the benefit of therapy in this
subtype amongst post-menopausal patients, but no differ-
ence in the magnitude of benefit was seen.23,24 In the same
way the Her-2 over-expression identified a more aggressive
phenotype of breast cancer due to a crosstalk between signal
transduction pathways and related to tamoxifen resistance.25
Until now there are no validated methods to select this sub-
type amongst a heterogeneous population in which, on aver-
age, the endocrine therapy has the same effects for all
subgroups; therefore, today the same hormonal treatment
must be given to all subtypes including those with PGR nega-
tive and Her-2+.
4. Timing and efficacy of ovarian ablation and
suppression
Use of either ovarian ablation or suppression with a luteinis-
ing hormone-releasing hormone (LHRH) analogue gave a
reduction of 30% in recurrence and breast cancer mortality
both in women younger than 40 years and aged 40–49 years.17
Moreover, this benefit is consistent across the years, underlin-
ing a sustained late effect with ovarian ablation. According to
these findings, a still open question is if a short course of
LHRH (2 or 3 years) could replace the permanent ablation.
The Overview included trials in which all methods of ovarian
ablation (radiation or surgical menopause) were considered
and oestrogen receptor status was available. Recently, a
meta-analysis based on individual patient data, including
only trials with LHRH analogues and patients with hormone
receptor positive, assessed the benefit of using LHRH ana-
logue only.26 The use of LHRH analogue as sole therapy did
not give a reduction in risk of recurrence and death, probably
for the small number of patients in this group, or for the short
course of LHRH adopted. Similarly, LHRH plus tamoxifen did
not affect the risk of recurrence on death, over tamoxifen
alone26 (Table 1). The addition of LHRH to chemotherapy orreast cancer overview group meta-analysis
Death after recurrence
P HR 95% CI P
0.08 0.82 0.47–1.43 0.49
0.20 0.84 0.59–1.19 0.33
0.01 –27.3 –44.4 to –4.9 0.02
0.55 –5.3 –24.2 to 18.3 0.63
0.01 –28.3 –44.9 to –6.8 0.01
0.63 –7.5 –25 to 14.1 0.47
0.52 0.93 0.79 to 1.10 0.40
ratio; CT, chemotherapy.
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recurrence, but a benefit was evident in the chemotherapy
alone group for the patients younger than 40 years26–28 (Table
1). LHRH meta-analysis compared chemotherapy versus
LHRH alone and like previous studies that investigated the
same comparison29–32 did not find any difference in risk of
recurrence or death independently by age26 (Table 1).
We must consider that the LHRH meta-analysis and the
previous studies that compare it to chemotherapy included
mostly CMF as chemotherapy regimen, only 32% used anthra-
cyclines-based regimen nor taxanes were used, none contain-
ing tamoxifen, resulting suboptimal in both arms.5. Aromatase inhibitors in pre-menopausal
patients
In pre-menopausal women, AIs have not been shown to be
effective and indeed cause negative feedback to the pituitary
gland, resulting in surges of oestrogens, which may be more
likely to increase breast cancer cell growth than have benefi-
cial effect.33,34 Moreover, their use is not indicated in patients
that have cessation of menses after chemotherapy, in fact
during therapy with aromatase inhibitors it is possible a re-
turn of ovarian function causing at the same time a reduced
anticancer efficacy and a risk of unwanted pregnancy. Cau-
tion must be taken also in patients nearly 50 years after many
months of amenorrhoea. In these women, a strict monitoring
of FSH, LH and estradiol must be done, in case of use of an
AI.35 Actually this question remains open and it is under
investigation in two ongoing trials: (1) SOFT trial (suppression
of ovarian function trial) randomised pre-menopausal pa-
tients treated or not with chemotherapy to receive tamoxifen
for 5 years versus OAS plus tamoxifen for 5 years versus OAS
plus Exemestane for 5 years and (2) TEXT trial (tamoxifen and
exemestane trial) randomised patients node negative or low
risk node positive, treated or not with chemotherapy, to re-
ceive 5 years of LHRH plus tamoxifen versus LHRH plus exe-
mestane.36–38Table 2 – Efficacy data from trial comparing AI in different
strategies to 5 years of tamoxifen
Trial AI Outcome
measure
HR 95% CI P value
Upfront trials
ATAC A DFS 0.85 0.76–0.94 0.003
BIG 1-98 L DFS 0.82 0.71–0.95 0.007
Switching trials
IES E DFS 0.76 0.66–0.88 0.0001
ABCSG8/ARNO 95 A EFS 0.60 0.44–0.81 0.0009
ITA A DFS 0.57 0.38–0.85 0.005
Extended trials
MA17 L DFS 0.58 0.45–0.76 <0.001
ABCSG 6a A EFS 0.64 0.41–0.99 0.048
ATAC, arimidex, tamoxifen alone or in combination trial; BIG 1-98,
breast international group; IES, intergroup exemestane study;
ABCSG, Austrian Breast Cancer Study Group.6. Endocrine therapy for post-menopausal
patients
Tamoxifen was the gold standard of endocrine therapy in
post-menopausal patients for two decades. The use of tamox-
ifen was associated with a 41% relative reduction in the risk of
recurrence and a 34% relative reduction in the risk of death in
patients with ER+ or ER unknown tumours.17 Aromatase
inhibitors (AIs) suppress plasma oestrogen levels in post-
menopausal patients by inhibiting or inactivating aromatase,
the enzyme responsible for the synthesis of oestrogen from
androgenic substrates. Anastrozole and letrozole are non-ste-
roidal inhibitors (type I, reversible), whereas exemestane is
steroidal (type II, irreversible).33 The AIs were used in clinical
trials with different modalities: soon after surgery (upfront),
after 2 or 3 years of tamoxifen (early switch) and after 5 years
of tamoxifen (extended switch).2–13 ATAC (arimidex, tamoxi-
fen, alone or in combination) trial investigated the role of
anastrozole upfront versus tamoxifen in post-menopausal
patients ER+. Recently, the results of this study, at a medianof 100 months of follow-up, became available. Disease free
survival, distant disease free survival, time to recurrence,
time to distant relapse and incidence of controlateral breast
cancer were significantly improved in the anastrozole arm;
moreover, the lower recurrence rate was constant even after
treatment was stopped. This suggests a carry-over effect of
anastrozole whose activity seems to be prolonged beyond
drug discontinuation.2 However, the overall survival of anas-
trozole treated patients was not different from that of tamox-
ifen treated patients. The BIG 1-98 (Breast International Study
Group) study randomised post-menopausal patients ER+ with
breast cancer, to receive upfront tamoxifen for 5 years versus
letrozole for 5 years, versus a sequence of the two drugs. The
use of letrozole, as compared to tamoxifen, led to a reduction
in the risk of an event comparable to that showed by anas-
trozole in the ATAC study3 (Table 2). In fact, also in this trial,
which has actually 51 months median follow-up, all efficacy
end-points, unless overall survival, were achieved by letroz-
ole. However, the results of the crossover arms are still not
available.
The design of sequential trials is based on pre-clinical
models in which prolonging tamoxifen exposure caused ac-
quired resistance,39,40 so the use of a non-cross-resistant
agent could be superior to tamoxifen alone. The largest trial
on this basis is the IES (Intergroup Exemestane Study) trial,
which randomised post-menopausal patients after two or
three years of tamoxifen to continue tamoxifen or to switch
to exemestane, for a total of 5 years.4,5 DFS and OS were better
for the switch strategy.5 Other studies with the same design,
such as Austrian Breast and Colorectal Cancer Study Group
(ABCSG), Arno 95 and ITA study showed a better DFS and OS
(unless for the ABCSG trial) for switching to anstrozole after
2 or 3 years of tamoxifen40 (Table 2). Moreover, a meta-analy-
sis based on individual patient data of trials with early switch
strategy only, gave an absolute benefit of OS that is about
3%.41
Given the risk of recurrence during the 15 years after the
diagnosis of breast cancer, an extended strategy was
investigated. MA-17 trial randomised women after 5 years of
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ter for patients in the letrozole group and a survival benefit
was seen amongst node-positive patients.10,13 There are no
data about the toxicity of AIs after 5 years and more informa-
tion is needed to establish the safety of a prolonged treat-
ment.13 NSABP B33 and ABCSG trial 6a showed in the same
way a beneficial of the extended therapy after five years of
tamoxifen, for exemestane and anastrozole, respectively11,12
(Table 2).
7. Selection of therapy in post-menopausal
patients
The main question in this population is the way to use AI, up-
front or sequential. The trials in which is present a small ben-
efit for OS are only the sequential trials: IES(5) study, MA17 for
the subgroups with node positive,12 the ARNO study, the
meta-analysis of ABCSG/ARNO and ITA studies.6–8 The princi-
pal criticism to these studies is that they do not consider the
recurrence occurred in the first two years because the ran-
domisation is performed after 2 or 3 years of tamoxifen;
moreover, they differ about the definition of DFS. Until the
publication of the final data from BIG1-98, there will be no
data to compare sequential strategy to upfront. Moreover,
many attempts have been done to construct an indirect com-
parison of different strategies by mathematical models. Pun-
glia et al.42 provided a model to compare the two strategies
and concluded that there is a modest survival benefit in fa-
vour of sequencing strategy. Another model proposed to ex-
plain the benefit of switching strategy is the so called deep
model43 suggesting that a proportion of hormonal receptors
could become PGR negative under the exposure to tamoxifen;
so in the context of a switching strategy it could be useful to
use an AI after two or three years of tamoxifen. This hypoth-
esis is not sustained by a recent evaluation in the context of
BIG 1-98 trial of the efficacy of letrozole according to the
expression of ER and PGR. In fact, this review did not confirm
the status of PGR as determinant for response to hormonal
therapy.23 The risk of recurrence for breast cancer remains
for several years after stopping hormonal therapy so the ex-
tended strategy could be a reasonable option to reduce this
risk. Two studies have showed a benefit to prolong therapy
after 5 years,10–13 but they differ about the definition of end-
points and actually we do not have a validate method to iden-
tify which patient is at a major risk of late recurrence; so the
extended therapy with AIs must not be considered a standard
therapy. Moreover, we must consider the profile of toxicity of
AIs and the potential risk with its prolonged use.8. Safety profile of endocrine therapy
Many side-effects of endocrine therapy, such as hot flushes
and mood disturbances, are related to oestrogen deprivation
and are common to tamoxifen and AIs, reflecting the mecha-
nism of action of these drugs. In addition, tamoxifen has oes-
trogenic effects that are beneficial in some tissues: tamoxifen
lowers serum cholesterol levels and protects against bone
loss and cardiovascular disease, but is also associated with
potentially life-threatening side-effects, such as endometrialcancer and thromboembolic disease. As AIs lack oestrogenic
activity, they are not associated with these serious adverse
events. Clinical trials comparing AIs with tamoxifen in the
adjuvant setting have shown that AIs are well tolerated and
are associated with a lower incidence of gynaecological
symptoms and hot flushes than tamoxifen. However, AIs
are associated with musculoskeletal side-effects, such as
arthralgia, myalgia and bone loss, but these events are pre-
ventable or manageable. The effects of AIs on lipid metabo-
lism and the cardiovascular system are still debatable, but
placebo-controlled trials provide no evidence to suggest that
AIs adversely affect these systems. It is worth of note, as
demonstrated in the ATAC 100 months results update, that
the increase in fracture rate, a side-effect expected during
use of anastrozole, dramatically decreased after drug
discontinuation.2
9. Conclusion
In pre-menopausal patients, tamoxifen in association with a
longer use of LHRH is the gold standard especially for patients
that continue to menstruate after chemotherapy, although it
is actually not possible to identify subgroups in which the
hormonal therapy has a little benefit. Aromatase inhibitors
must be usedwith caution in pre-menopausal patients amen-
orrheic after chemotherapy because of the potential recovery
of ovarian activity.
In post-menopausal patients we are waiting for more data
to identify the better strategy to use AIs, upfront or switching
strategy, actually both results valid. We need more data to ex-
tended therapy with AIs after 5 years and if we decide to pro-
long therapy we must outweigh benefit and risk of toxicities.
Thus, methods for improving the use of endocrine therapy,
such as exploring new classes of agents, dosing, scheduling,
combinations, and the addition of targeted agents to reduce
the development of resistance, are crucial for the next future.Conflict of interest statement
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